Irritable Bowel Syndrome
Conditions
Brief summary
Irritable bowel syndrome (IBS) is the most common functional GI disorder in which abdominal pain and/or discomfort is associated with changes in bowel habit, and with features of disordered defecation. IBS affects 10-20% of the population and causes a marked reduction of quality of life in affected individuals.The high prevalence of IBS is accompanied by large societal economic burdens and negative effects on the quality of life in affected patients. It is divided into 3 types IBS-D diarrhea predominant, IBS-C constipation predominant, IBS-M mixed sub type.
Detailed description
Irritable bowel syndrome (IBS) is the most common functional GI disorder affecting 10-20% of the population and causing a marked reduction of quality of life in affected individuals. An altered brain-gut axis has been accepted as a main pathogenetic mechanism of IBS, which is associated with a dysfunction of the GI autonomic nervous system. These alterations may lead to abnormal visceral hypersensitivity and aberrations of gut motility. Recently, additional potential mechanisms of IBS have emerged including alteration of gut microbiota and low-grade inflammation/immune activation. These factors might lead to abnormal motility and visceral hypersensitivity and contribute to the symptoms. Naïve gut microbiota plays important roles in the maintenance of gut homeostasis by direct bactericidal effects and the evolution of both innate and adaptive immune systems. Gut microbiota is thought to play important roles in the pathogenesis of IBS. This is evident from the fact that IBS occurs more frequently after intestinal infection or antibiotics treatment. Studies have shown that the alterations of the intestinal microbiota are observed in IBS patients.Considering the relationship between alteration of gut microbiota and inflammation of gut, manipulation of gut microbiota by probiotics appears to be an ideal treatment modality for IBS. However, the beneficial effects and efficacy of altering gut microbiota by probiotics to improve the symptoms of IBS have not been consistent in clinical trials and therefore it remains uncertain as an effective treatment.
Interventions
DRUGProbiotic VSL#3
DRUGPlacebo
Sponsors
Department of Gastroenterology, Govt. Medical College, Kozhikode, Kerala, India
Next Gen Pharma India Pvt. Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Positive diagnoses of IBS subtype IBS-D defined by Rome III criteria, and who meet the following criteria: a) Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) b) abdominal pain score of \> 3.0 on a 0 to 10 point scale & c) Stool Consistency of at least one stool with a consistency of Type 6 or Type 7 Bristol stool score (BSS) on at least 2 days per week 2. Signed informed consent
Exclusion criteria
1. Patients currently using non-steroidal anti-inflammatory drugs, corticosteroids and mast cell stabilizers, or topical or systemic antibiotics in the past 1 month. 2. Patients with major abdominal surgery, a history of inflammatory bowel disease or diverticular disease, celiac disease (by detection of anti-transglutaminase and anti-endomysial antibodies), allergic diseases, including asthma (excluded by family and personal history and specific anti-IgE antibodies), and other organic or psychiatric disorders as assessed by medical history, appropriate consultations and laboratory tests. 3. Females who are Pregnant, breast-feeding, or not using reliable methods of contraception
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the intensity of abdominal pain relief and change in stool consistency before and after treatment, between the two arms | 8 wks (after end of treatment) | The defecation component of the primary endpoint will be evaluated by assessing stool consistency as per Bristol Stool Form Scale. Abdominal pain component of primary end point will be accessed by using an 11-point (i.e., 0 to 10) numeric rating scale that asks patients daily to rate their worst abdominal pain over the past 24-hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of Quality of Life parameters as measured by IBS-QoL Questionnaire before and after treatment, between the 2 arms | 8 wks (after end of treatment) and 20 weeks (12 weeks after end of follow-up period; at end of study) | — |
| Comparison of Quality of Life parameters as measured by SF-36 Questionnaire before and after treatment, between the 2 arms | 8 wks (after end of treatment) and 20 weeks (12 weeks after end of follow-up period; at end of study) | — |
| Comparison of Visceral hypersensitivity/Rectal sensitivity before and after treatment between the two arms | 8 wks (after end of treatment) | Visceral hypersensitivity/Rectal sensitivity as measured between and within arms using a lubricated rectal balloon catheter for the duration taken for first defecation, first instance of pain and the pain threshold |
Countries
India
Outcome results
None listed